July 19, 2024

Antipsychotic Drugs Market Size to Rake USD 31.37 Bn by 2033

The global antipsychotic drugs market size was estimated at USD 17.43 billion in 2023 and is predicted to rake around USD 31.37 billion by 2033, growing at a CAGR of 6.05% from 2024 to 2033.

Key Points

  • North America held the largest share of the market share of 53% in 2023.
  • Europe is anticipated to gain a considerable market share in the upcoming years.
  • By disease, the schizophrenia segment dominated the market in 2023.
  • By disease, the bipolar disorder segment is observed to carry a significant share over the forecast period.
  • By therapeutic class, the second-generation segment dominated the market in 2023.
  • By therapeutic class, the third-generation segment is expected to grow at the fastest rate during the forecast period.
  • By drug, the aripiprazole segment held a significant share of the market in 2023.
  • By drug, the paliperidone palmitate segment is expected to grow at a significant rate during the forecast period.
  • By distribution channel, the hospital pharmacies segment is expected to hold the largest market share during the forecast period.
  • By distribution channel, the drug stores & retail pharmacies segment is expected to witness a notable rate of growth during the forecast period.

Antipsychotic Drugs Market Size 2024 to 2033

The antipsychotic drugs market is a crucial segment of the pharmaceutical industry, dedicated to addressing various psychiatric disorders such as schizophrenia, bipolar disorder, and major depressive disorder. These drugs work by modulating neurotransmitter activity in the brain, particularly dopamine and serotonin, to alleviate symptoms associated with psychosis and mood disorders. With the rising prevalence of mental health disorders globally, the demand for antipsychotic drugs continues to grow steadily, driving significant developments in drug research, manufacturing, and distribution.

Get a Sample: https://www.precedenceresearch.com/sample/3992

Growth Factors

Several factors contribute to the growth of the antipsychotic drugs market. One primary driver is the increasing recognition and diagnosis of psychiatric disorders worldwide. As awareness about mental health issues improves and stigma reduces, more individuals seek medical help, leading to a higher demand for antipsychotic medications. Additionally, advancements in pharmacology and neuroscience have spurred the development of newer, more effective antipsychotic drugs with improved safety profiles, enhancing patient outcomes and driving market growth.

Moreover, the aging population in many regions is a significant growth factor for the antipsychotic drugs market. Elderly individuals are more prone to psychiatric disorders such as dementia-related psychosis and require pharmacological interventions to manage symptoms effectively. As the global population continues to age, the demand for antipsychotic medications is expected to rise, bolstering market expansion.

Furthermore, the expanding healthcare infrastructure in developing countries, coupled with increasing healthcare expenditure, contributes to market growth. Improved access to healthcare services enables more individuals to receive diagnosis and treatment for psychiatric disorders, thereby driving the demand for antipsychotic drugs in emerging markets.

Region Insights:

The antipsychotic drugs market exhibits regional variations influenced by factors such as healthcare infrastructure, regulatory environment, prevalence of psychiatric disorders, and socioeconomic conditions. North America and Europe currently dominate the market, attributed to the high prevalence of mental health disorders, well-established healthcare systems, and robust pharmaceutical industries in these regions. Additionally, extensive research and development activities in North America and Europe contribute to the introduction of innovative antipsychotic medications, further consolidating their market position.

In contrast, Asia Pacific presents significant growth opportunities for the antipsychotic drugs market. Rapid urbanization, changing lifestyles, and increasing awareness about mental health issues drive the demand for psychiatric treatments in countries like China, India, and Japan. Moreover, initiatives aimed at improving mental healthcare access and reducing stigma contribute to market growth in the region.

Latin America and the Middle East & Africa region also exhibit growth potential for the antipsychotic drugs market, albeit at a slower pace compared to other regions. Limited access to healthcare services, socioeconomic challenges, and cultural factors pose barriers to market expansion in these regions. However, efforts to strengthen healthcare infrastructure and increase awareness about mental health disorders are expected to fuel market growth in the long term.

Antipsychotic Drugs Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 6.05%
Global Market Size in 2023 USD 17.43 Billion
Global Market Size by 2033 USD 31.37 Billion
U.S. Market Size in 2023 USD 6.47 Billion
U.S. Market Size by 2033 USD 11.64 Billion
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Therapeutic Class, By Disease, By Drug, and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Antipsychotic Drugs Market Dynamics


Several drivers propel the growth of the antipsychotic drugs market. Firstly, ongoing research and development activities focused on discovering novel drug targets and formulations drive innovation in the field. Emerging trends such as personalized medicine and precision psychiatry hold promise for the development of tailored treatment regimens, enhancing the efficacy and safety of antipsychotic medications.

Additionally, collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare organizations accelerate drug development and market penetration. Strategic alliances facilitate the sharing of resources, expertise, and intellectual property, leading to the expedited development of new antipsychotic drugs and expanded market reach.

Moreover, the integration of digital health technologies such as telemedicine, mobile apps, and electronic health records enhances patient engagement and adherence to treatment regimens. Digital platforms offer tools for remote monitoring, medication management, and psychoeducation, improving patient outcomes and reducing healthcare costs associated with psychiatric disorders.

Furthermore, increasing investment in mental health awareness campaigns and advocacy initiatives fosters destigmatization and encourages individuals to seek timely diagnosis and treatment. Public health efforts aimed at promoting mental well-being and early intervention contribute to the growing acceptance and utilization of antipsychotic drugs among patients and healthcare providers.


The antipsychotic drugs market presents numerous opportunities for stakeholders to capitalize on emerging trends and unmet needs. One such opportunity lies in the development of long-acting injectable formulations of antipsychotic medications. These formulations offer several advantages over oral medications, including improved adherence, reduced risk of relapse, and enhanced convenience for patients and healthcare providers. The growing interest in long-acting injectables presents opportunities for pharmaceutical companies to expand their product portfolios and cater to diverse patient populations.

Moreover, the rising adoption of digital therapeutics and artificial intelligence in mental healthcare presents a promising opportunity for innovation in the antipsychotic drugs market. Digital interventions such as cognitive behavioral therapy apps, virtual reality-based exposure therapy, and smartphone-based monitoring tools complement pharmacological treatments, offering holistic approaches to managing psychiatric disorders. Pharmaceutical companies can explore partnerships with technology firms to develop integrated treatment solutions that combine digital therapeutics with traditional pharmacotherapy, catering to the evolving needs of patients and healthcare providers.

Furthermore, the expanding application of antipsychotic drugs beyond traditional psychiatric indications presents new avenues for market growth. Research indicates potential benefits of antipsychotic medications in treating conditions such as autism spectrum disorder, post-traumatic stress disorder, and substance use disorders. Exploring these off-label indications and securing regulatory approvals for expanded indications can unlock new market opportunities and diversify revenue streams for pharmaceutical companies.


Despite the favorable market dynamics, the antipsychotic drugs market faces several restraints that may impede growth. One significant restraint is the presence of generic competition, particularly for older, off-patent antipsychotic medications. Generic manufacturers offer lower-priced alternatives, leading to pricing pressures and reduced profit margins for branded pharmaceutical companies. Additionally, the availability of generic versions may hinder the market uptake of newer, branded antipsychotic drugs, especially in cost-conscious healthcare settings.

Moreover, concerns regarding the safety and tolerability of antipsychotic medications pose a restraint to market growth. Adverse effects such as metabolic disturbances, weight gain, extrapyramidal symptoms, and cardiovascular complications are associated with long-term use of certain antipsychotic drugs. Healthcare providers and patients may exhibit reluctance towards initiating or maintaining treatment with antipsychotic medications due to these safety concerns, leading to suboptimal treatment outcomes and decreased market demand.

Furthermore, regulatory challenges and stringent approval processes pose barriers to market entry for new antipsychotic drugs. Regulatory agencies impose rigorous requirements for demonstrating efficacy, safety, and quality standards, prolonging the drug development timeline and increasing development costs. Delays in regulatory approvals or unfavorable regulatory decisions can significantly impact market access and commercialization prospects for pharmaceutical companies, deterring investment in antipsychotic drug development.

Additionally, societal perceptions and cultural attitudes towards psychiatric medications may influence patient preferences and treatment-seeking behaviors. Stigma associated with mental illness and medication adherence may lead to underutilization of antipsychotic drugs, particularly in certain demographic groups or geographic regions. Addressing stigma through education, advocacy, and community engagement efforts is essential to overcoming this restraint and promoting acceptance of psychiatric treatments.

Read Also: Wire and Cable Polymer Market Size to Worth USD 14.58 Bn by 2033

Recent Developments

  • In January 2023, Luye Pharma Group received the Food and Drug Administration approval for Rykindo to treat schizophrenia and bipolar disorders.
  • In February 2022, Alkermes plc released positive results from ENLIGHTEN-early, a phase 3b study that evaluates the study of LYBALVI in schizophrenia disease.
  • In January 2022, Otsuka Pharmaceutical Co., Ltd., its subsidiary Otsuka American Pharmaceutical, Inc., and Lundbeck, Inc. received the Food and Drug Administration approval for the supplemental new drug application of REXULTI for Schizophrenia in 13 to 17-year-old patients.
  • In February 2022, Alkermes plc released encouraging results from ENLIGHTEN-early, a phase 3b research that evaluated the effectiveness of LYBALVI in the treatment of schizophrenia disorder.

Antipsychotic Drugs Market Companies

  • Eli Lily and Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co, Ltd.
  • Pfizer Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Teva Pharmaceuticals
  • Dr. Reddy’s Laboratories

Segments Covered in the Report

By Therapeutic Class

  • First Generation
  • Second Generation
  • Third Generation

By Disease

  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Depression
  • Dementia
  • Other Diseases

By Drug

  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/



I have completed my education in Bachelors in Computer Application. A focused learner having a keen interest in the field of digital marketing, SEO, SMM, and Google Analytics enthusiastic to learn new things along with building leadership skills.

View all posts by Prathamesh →

Leave a Reply

Your email address will not be published. Required fields are marked *